Characteristics | Total n (%) |
---|---|
Age (months) | |
<12 | 3 (3.7) |
12–18 | 4 (4.9) |
18–24 | 11 (13.6) |
>24 | 63 (77.8) |
Gender | |
Male | 51 (63.0) |
Female | 30 (37.0) |
Treatment group | |
LR | 3 (3.7) |
IR | 3 (3.7) |
HR | 75 (92.6) |
Clinical stage | |
IV | 81 (100) |
MYCN gene | |
Amplification | 13 (16.0) |
Normal | 68 (84.0) |
LDH (IU/L) | |
<1500 | 55 (67.9) |
≥1500 | 26 (31.1) |
NSE (UG/L) | |
<100 | 10 (12.3) |
≥100 | 71 (87.7) |
Primary site | |
Abdomen | 73 (90.1) |
Thorax | 6 (7.4) |
Others | 2 (2.5) |
Event | |
No event | 54 (66.7) |
Relapse | 20 (24.7) |
Death | 7 (8.6) |